Six months ago start-up firm Epiphany Biosciences in-licensed a compound for varicella zoster virus. With the closing of a $36 million Series A round, the company now is poised to advance that product through Phase IIb trials, as well as continue work on a blood-screening product for herpesvirus-8. (BioWorld Today)
Six months ago start-up firm Epiphany Biosciences in-licensed a compound for varicella zoster virus. With the closing of a $36 million Series A round, the company now is poised to advance that product through Phase IIb trials, as well as continue work on a blood-screening product for herpesvirus-8. (BioWorld Today)
Oxford BioMedica plc, of Oxford, UK, agreed to acquire neighboring Oxxon Therapeutics Ltd., in an all-share transaction valued at about £16 million (US$30.9 million). (BioWorld Today)
Oxford BioMedica plc, of Oxford, UK, agreed to acquire neighboring Oxxon Therapeutics Ltd., in an all-share transaction valued at about £16 million (US$30.9 million). (BioWorld Today)
